Has Deborah Dougherty received payments from drug or device companies?

Yes. Drug and device makers reported $5,225 in general payments to Deborah Dougherty across 244 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Deborah Dougherty did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Deborah Dougherty come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Deborah Dougherty

Family · Vienna, VANPI 1760487821

Payments from drug & device makers

$5,225in general payments, 2019–2025

Across 244 payments — averaging $21.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
Otsuka America Pharmaceutical, Inc.$1K
Lundbeck LLC$545
AbbVie$344
E.r. Squibb & Sons, L.L.C.$338
Neurocrine Biosciences, Inc.$297
plus $799 from 10 others

What the payments were for

Food & beverage$5,11798%
Education$1082%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	68	$1,548
Otsuka America Pharmaceutical, Inc.	49	$1,356
Lundbeck LLC	28	$545
AbbVie	23	$344
E.r. Squibb & Sons, L.L.C.	21	$338
Neurocrine Biosciences, Inc.	13	$297
Vanda Pharmaceuticals Inc.	12	$195
Alkermes, Inc.	7	$187
Sunovion Pharmaceuticals Inc.	7	$144
Supernus Pharmaceuticals, Inc.	6	$109
Teva Pharmaceuticals USA, Inc.	4	$68
Corium, LLC	2	$23
Takeda Pharmaceuticals U.S.A., Inc.	1	$21
Indivior Inc.	1	$19
Johnson & Johnson	1	$19
Tris Pharma Inc	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,225 in reported general payments places this provider in the 90th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
CaplytaLumateperone Tosylate	18	$29,573
RexultiBrexpiprazole	13	$19,866
TrintellixVortioxetine Hydrobromide	12	$9,638
Lisdexamfetamine Dimesylate	14	$3,173
Lurasidone Hcl	11	$2,220
Desvenlafaxine Succinate ErDesvenlafaxine Succinate	21	$1,608
Aripiprazole	23	$1,316
Bupropion XlBupropion Hcl	70	$1,161
Perphenazine	17	$1,010
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine	18	$721
Prazosin Hcl	15	$558
Venlafaxine Hcl ErVenlafaxine Hcl	15	$408
Buspirone Hcl	48	$376
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine	16	$357
Duloxetine Hcl	15	$337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta	$1,548	$29,57318 claims
Otsuka America Pharmaceutical, Inc.Rexulti	$1,356	$19,86613 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix	$21	$9,63812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,332 family providers in Virginia.

Other family in Vienna

Andrea CottonVirginia Beach$696K
Susan MooreWytheville$438K
Ellen WermterCharlottesville$251K
Dana StallingsFranklin$225K
Jocelyn BrackettHerndon$199K
Hochong Smith GillesRichmond$131K
Sean OlaughlinMidlothian$110K
Adam MedlinHampton$67K
Casey SharpDanville$63K
Norman JacobowitzManassas$55K

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →